Lite Strategy (LITS) Change in Receivables (2021)

Lite Strategy (LITS) posted Change in Receivables of -$10.0 million for Q4 2021, down 200.0% on a QoQ basis from $10.0 million in Q3 2021.

Analysis

Lite Strategy (LITS) Change in Receivables (2021) Analysis & Trends

Lite Strategy has reported Change in Receivables for 1 years, with the latest figure at -$10.0 million in Q4 2021.

On a quarterly basis, Change in Receivables changed N/A year-over-year to -$10.0 million in Q4 2021; TTM through Mar 2022 was $25.1 million, a N/A change from a year earlier, with the FY2021 full-year figure at $4.7 million, up 101.28% from the prior year.
Change in Receivables was -$10.0 million for Q4 2021 at Lite Strategy, down from $10.0 million in the prior quarter.
The five-year high for Change in Receivables was $25.1 million in Q2 2021, with the low at -$10.0 million in Q4 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn	1.09 Bn
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn	333.00 Mn
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn	140.20 Mn
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn	838.50 Mn
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn	-
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn	-53.00 Mn
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn	31.60 Mn
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn	269.40 Mn
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn	-
10	Lite Strategy	38.03 Mn	30.49 Mn	-	-

Historic Data

Download Data